Acquisition Opportunity There is strong indication of ACS activity and potential acquisition by Abbott in 2023, signaling a consolidation in the cardiovascular medical device space. Sales teams should tailor outreach to Abbott or similar large incumbents with CSI’s atherectomy and PAD solutions as strategic bolt-ons.

Calcium Intervention CSI emphasizes addressing arterial calcium in complex PCI and PAD, suggesting sustained demand for advanced plaque modification and atherectomy devices. Target interventional cardiology and peripheral intervention programs seeking innovative calcium management technologies.

Line Expansion Past partnerships and asset acquisitions indicate CSI’s growth via broadening product lines, notably thrombectomy devices and peripheral/coronary offerings. A sales angle could be packaged solutions integrating multi-device kits for comprehensive revascularization.

Financial Health Estimated revenue in the low hundreds of millions with substantial funding and recent M&A activity imply resources and potential for scaled deployments, managed rollouts, or co-development deals with larger OEMs and distributors.

Global Outreach CSI’s manufacturing focus and core values, plus a visible online presence and engagement with major industry players, present opportunities to expand distributor networks, training programs, and service/support partnerships to accelerate adoption.